Hims & Hers Health (NYSE:HIMS) COO Sells $2,402,065.41 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 97,289 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. This trade represents a 19.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Hims & Hers Health Stock Down 9.0%

Hims & Hers Health stock opened at $21.99 on Friday. The stock has a 50 day moving average of $22.80 and a two-hundred day moving average of $36.75. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The stock has a market capitalization of $5.01 billion, a price-to-earnings ratio of 43.13, a PEG ratio of 2.71 and a beta of 2.55. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its position in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. Capital World Investors lifted its position in shares of Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp raised its holdings in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several recent analyst reports. BTIG Research cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Morgan Stanley dropped their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Truist Financial reissued a “hold” rating and set a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Leerink Partners lifted their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Finally, Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $31.29.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.